DETROIT, July 8 /PRNewswire/ -- At 12:00 noon on July 8, 2008, J. Douglas Peters, an attorney with Detroit's Charfoos & Christensen, P.C., filed the first drug product liability action in a Michigan Court since the Michigan Supreme Court affirmed former Governor Engler's grant of immunity to drug manufacturers.
The class action drug product liability lawsuit was filed in the United States District Court, Eastern District of Michigan, Southern Division, by plaintiffs Anthony Harris (Redford) and Steven B. Love (Kentwater) against Activis Group (formerly known as Amide Pharmaceutical), Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc., et al, claiming damages in excess of $75,000.00.
Digitek(R), the trade name for the drug in question, is the brand name for digitalis, a drug given to heart patients. During the manufacturing process, errors were made such that the .125 mg labeled tablet was actually .250 mg; and, the tablet sold as .25 mg was actually .50 mg. This manufacturing error is not covered by the broad grant of immunity Governor Engler intended when Michigan's drug manufacturer immunity legislation was adopted during the Engler Administration.
Death from ventricular arrhythmia, or heart block, can result from digitalis overdose. Non-fatal complications can include nausea, vomiting, severe weight loss, diarrhea, mental confusion, vision changes and elevated blood pressure, which can lead to cerebral strokes.
The filing of this class action lawsuit in Michigan prevents the statute of limitations for other Michigan citizens from expiring. This is helpful because some, but not all recipients of Digitek(R), received letters from their pharmacies recalling the misbranded drugs.
According to Peters, "I sure hope that the manufacturing errors by
these major pharmaceutical companies are not given the cloak of immunity by
the conservative majority that currently controls the Michigan Supreme
Court. To give immunity to manuf
|SOURCE Charfoos & Christensen, P.C.|
Copyright©2008 PR Newswire.
All rights reserved